Management Development

Yu (James) Shao

* ******** **., ******* *****, NJ 07920

Mobile: 908-***-****; Email: **.*.****@*****.***

. Pharmaceutical Consumer Healthcare R&D Head with extensive leadership

and operation experience in building and leading cross-functional team

including medical affairs, clinical operation, regulatory, new product

development, Technology transfer and deployment, new product research,

pipeline management, quality & compliance, project management,

packaging development & outsourcing

. Proven outstanding track records in delivering new innovative products

to markets (key roles for 8 new product launches in 8 years with GSK

USA, 25 new product launches for GSK China in 4 and half years as Head

of R&D China).

. Built strong sustainable innovation strategy and pipeline for GSK

China consumer healthcare business in Pain Management, Respiratory

Health, Skin Health, and Oral Health. Innovation sales grow from 3% in

2008 to 16% in 2012 to 25% in 2016.

. Co-partner with commercial VP to own innovation vision and strategy,

innovation P&L, execution and delivery of the strategy.

. Developed differentiating and competitive scientific stories for every

new product to compete and win in consumer and expert marketing

channels.

. Successful experiences with regulatory submissions and approvals with

FDA, MHRA, EMEA, TGA and CFDA for Rx-to-OTC switch, NDA, and Medical

Device, Cosmetic, Antiseptic, and Functional food.

. Created and developed two R&D new organization and innovation centres

for GSK China from scratch within 4 years, and developed local

successor and leadership team.

. Transferred R&D lab, Quality system and pilot plant from Tianjing to

Taizhou/Shanghai

. Led the assessment and selection of strategic 3rd party manufacturing

partners in China, and implemented GSK quality system into 3rd parties

for various products, solid dosage form, liquid and Semi-solids, and

powder etc.

. Managed & prioritized R&D resources and budget to achieve optimum

return on investment

. Innovation Guru for pharmaceutical and healthcare products including

Rx, OTC, and Rx-OTC switches Cosmetic, Antiseptic, Medical Devices,

dietary supplement and Food etc.

. Deep insights and knowledge on the tough Chinese regulatory

environment, pricing policy, and the pathway of introducing new

products to China markets

. Well connected with Chinese KOLs, and Chinese regulatory agencies and

key industry associations

. Created due diligence process for M&A and license-in to strengthen

existing business and provide new growth opportunities and diversify

the company's business portfolio

. Institutionalized innovation gate process, project management process,

and new product development process from early research to product

launches.

. Established licensing-in team, and pathway of bringing in new products

and technologies from 3rd parties.

. Productive scientist with strong track record in peer-reviewed journal

publication

. Superior and Proven expertise in solving complex technical and

business problems

. Passionate, energetic, technically superb, strategic and results-

driven professional

. Inventor and author of over 60 patents and peer-review publications in

various area

PROFESSIONAL EXPERIENCE:

GlaxoSmithKline Consumer Healthcare, Singapore/US/Shanghai/US, R&D Head of

China Category and R&D Lead for Transferring Global Pain

Management and Nutrition R&D to Singapore, March 2013 to

Present

. Reports to R&D global head SVP on the setup of Global Pain Management

and Nutrition R&D team and facility in Singapore

. A member of Global R&D Senior Leadership Team

. Set up strategic partnership with Economy Development Board of

Singapore

. Created way of working for Singapore R&D team

. Assessed and built strategic local KOL networks for coming Singapore

pain management and nuts R&D

. Set up business continuity plan with a focus on Pain Management

subcategory R&D

. Set up Singapore Innovation Hub

. Selected global recruitment agencies, recruitment process, and

streamlined job description of over 18 roles.

. Identified highly talented candidates for R&D, medical and

regulatory from around the world, and currently being in the process

of interview with a target of hiring all roles by end of Aug 2013.

. Managed the smooth handover and transition of China R&D leadership

role to the successor to ensure the business continuity.

GlaxoSmithKline Consumer Healthcare, China, Jan 2009 to Feb 2013

Head & Sr. Director, China Category R&D, Shanghai/Beijing/Tianjin, Jan

2011 to Feb 2013

. Reports to Global R&D VP on innovation and organization

. A member of Global R&D Senior Leadership Team and China Area Senior

Leadership Team

. Established a new R&D innovation centre with 60 staff in Shanghai

within 2 years in addition to R&D teams in Beijing/Tianjin.

. Worked with commercial head to co-lead China category team (R&D,

marketing, insights, supply chain, HR and Finance) to build innovation

competence, process and system, and create innovation strategy to fuel

commercial growth

. Delivered 15 new product launches in 2011/2012 which contributed to

16% of total sales. Critically contributed to GSK Cx 20% China growth

in last 4 years

. Expanded the existing product categories to adjacent subcategories

from pain management, respiratory, wound care, GI, hypersensitivity to

nasal decongestion, allergy, sore throat, cough, dermatitis, smoking

reduction, oral gum care, and dental care etc.

. Established short term and long term pain management innovation

pipeline in oral form and topical including the defence strategy of

Ibuprofen SR capsule 300 mg under Fenbid brand, launching 400 mg SR

capsule, obtaining NDA approval of Ibuprofen chewable, launching

Fenbid headache, developing menstrual pain hot remedy, developing

Diclofenac gel and patches, licensing-in hydrogel patch and entering

into the development of non-OTC massage gel etc.

. Established the innovation strategy and pipeline for Respiratory

(Contac brand) including defence strategy of PSE products, introducing

decongestion Breathe Right to China, launching and developing Sore

Throat products from food to functional food to OTC, licensing cough

products

. Established the innovation strategy and pipeline for Skin Health

including launching would wash, developing wound protection membrane,

launching dermatitis/eczema, developing acne products, and licensing

in acne OTC product.

. Established Oral care innovation strategy and pipeline including

introducing Sensodyne global new products to china, introducing

Polident global products to China, developing Gum care products, and

developing Sensodyne Natural and sensory improvement.

. Established centre of excellence for clinical operation in serving

global clinical trials in China

. Established a team of 19 medical affairs in support of innovation, new

product registration (preclinical, phase I/II/III), medical

governance, PV and safety, phase IV clinical studies, Scientific

engagement with local key opinion leaders

. Created and drove "every product is famous of its science" to support

expert and consumer marketing

. Managed complex stakeholders within country and above country to

ensure alignment and support

. Drove clinical or in vitro studies to generate or support product

claims

. Established open innovation, license-in capabilities and 2 new

products will be introduced through license-in in 2013 and 2014,

respectively

. Developed a consumer insight driven and science based innovation

pipeline which can deliver innovation contribution up to 25% for

commercial by 2016.

. Worked with industry associations and Chinese regulatory agencies to

shape or influence China regulation.

. Established new innovation gate process, resource and budget

management and prioritization process

. Drove IP creation, and multiple patents were granted. IP is core

strategy of pricing defence and product differentiation

. Developed talent and succession plan for critical roles.

. Transferred R&D lab, OTC GMP pilot plant and quality system from

Tianjin to Taizhou/Shanghai.

. Assessed and selected strategic partners of 3rd party/contract

manufacturing in China to complement GSK China manufacturing

capabilities. Implemented GSK quality system into 3rd parties to meet

GSK standards. New product Bactroban liquid spray (Antiseptic), Contac

sore throat (Health Food), Contac Cough (OTC granule), and Sensodyne

toothpastes (Semi-solids) are being successfully supplied by 3rd

parties in China.

. Chaired the leadership committee of GSK new product technology

transfer and troubleshooting which is consisted of Site leader of

manufacturing site, R&D NPD Head, Supply chain Head, Technology

transfer Head, Quality Head, and Regulatory Head.

. Sponsored and led the implementation of QbD, OE, and Value

engineering programs for R&D and Manufacturing sites.

. Drove Traditional Chinese Medicine market entry strategy, and global

clearance and acceptance on TCM.

. Switched one TCM topical product from Rx to OTC, and the launch is

pending the medical clearance from GSK safety board.

Head & Director, TSKF R&D, GlaxoSmithKline Consumer Healthcare,

Beijing/Tianjin, Jan 2009 to Dec 2010

. Reported to global R&D VP

. Re-structured TSKF R&D organization, and transformed the organization

from a service org to an innovation power house within 2 years

. Launched 8 new products for TSKF in 2 years which contributed to 14 %

of total sales (2009/2010)

. Established new product pipeline with a good balance of short, near

and long term for China local brands Fenbid (Pain Management), Contac

(Respiratory), Bactroban (Wound Care)

. Introduced Oral Care global products Sensodyne and Polident to China

. Established China Portfolio Management Board

. Implemented the project management E2E and new product development

process

. Created China Oral Health Innovation Centre in Beijing

. Significantly lift up the employee engagement of R&D (from 19% to 53%)

. Significantly lift up the regulatory and medical capabilities.

. Created technology deployment capabilities.

. Transferred R&D lab, OTC GMP pilot plant and quality system from

Tianjin to Taizhou.

. Transferred a tablet product from GSK TSKF factory to GSK Tianjing 2nd

Factory.

. Created new product research and packaging capabilities

. Created outsourcing networks and partners for R&D to increase

organization capability, capacity, and efficiency

. On-air television spokesperson for Sensodyne in China.

. Led and drove initiatives of bringing Traditional Chinese Medicine

into GSK China including a series of programs: Education of Central

Leadership on TCM, commercial and consumer understanding, drafting and

aligning GSK TCM guidances on the quality, efficacy and safety

requirements.

GlaxoSmithKline Consumer Healthcare, Parsippany, New Jersey, July 2000 to

Dec 2008

Group Leader/Director, Weight Control, New Product Development, Oct

2007 to Dec 2008

. Reported to Global New Product Development VP

. Led a team of over 10 scientists in formulation, process, and

analytical development and transfer

. Played critical role in preparing CMC, and answering agency questions

for the successful approval of Weight control orlistat capsule (Alli)

in EU markets

. R&D leader to transfer Olistat capsule manufacturing from Roche site

to GSK Aiken SC site.

. Led the development and manufacturing technology transfer of a lower

dose Orlistat tablet with improvement of efficacy and less side

effect.

. Provided leadership and strategic direction in the delivery of PDBs

and EPDB projects for the Weight Control NPD group which are directly

in line with global marketing team, regulatory and medical strategies.

. Sponsored and initiated the Weight Control IP strategy core team.

. Sponsored and initiated the Weight Control in vitro lipolysis method

strategy core team. In-depth scientific evaluation and understanding

on the previous multiple approaches led to a single, and clear in

vitro strategy in predicting the BE dose of new formulations using in

vitro methods prior to the clinical trial.

. Reached external networks to identify the scientific experts in

enzymology, physiology and inhibition of lipase.

. Reached external networks to source the innovative technologies.

Working with Jintan to develop seamless soft gel to enhance the

efficacy of Orlistat

. Rolled out QbD/Value engineering/OE training and ensured the

application for every new product development.

Team Leader/Principal Scientist, Nasal Decongestion/Smoking Control,

Feb 2006 to Sept 2007

. Delivered 3 new product launches, Breathe Right kids, Breathe Right

Extra Strength, and Breathe Right Next Generation

. Initiated and established the important strategic approach with 3M on

adhesive development to secure the exclusive supply of current BRNS

adhesive and to lock 3M as developing partner of new adhesives.

. Laid out NPD strategies on Breathe Right: IP development (NexGen,

AirFlex, and 3M patent), spring material characterization (ME&Tlab),

Adhesive characterization (National Polymer lab), and Skin Testing (Hi-

Tech Lab).

. Established external development partnerships with 3M, Avery, Dow

corning, and Euromed to conduct the screening of all types of

adhesives, Acrylate, Synthetic rubber based, Silicon-based, and

Hydrocolloids

. Implemented GSK quality system for Breathe Right manufacturing 3rd

Party WebTech Inc.

. R&D leader to solve GSK Aiken manufacturing and analytical testing

issue of Nicotine Lozenges.

. Led the Smoking control open innovation project Allergo.

. Led the 2006/2007 Company Top Talent program.

Principal Scientist, Smoking Control/Pain Management, Sept 03 to Jan 06

. Project Leader for Smoking Control Nicotine Lozenges (Commit

Cherry & Cappuccinio & Mint):

o Led project team across R&D functions to successfully obtain

the approval of this product from FDA on time.

o Led NPD scientists to conduct DOE in thoroughly

understanding the key technical issue of dissolution.

o Formulated the technical strategy, and execute the design of

experiments for the selection of cherry and coffee flavours

which presented tremendous stability challenges.

o Led NPD scientists to conduct formulation development,

process development, technology transfer, method development

and validation, and SUPAC in-vitro testing

. Project Leader for a fast disintegrated tablet (Caffeine and

Paracetamol, Panadol) for Pain Management

o Led team to optimize formulation and process, and the

dissolution issue was resolved.

o Led team to define regulatory/medical, and analytical

strategy

o Product was launched

. Provided analytical guidance to GSK Pharma to develop suitable

analytical methods for Nicotine Inhaler, and to conduct in-vitro

testing using in vitro model, Anderson Compactor.

. US New Technology Champion: Led a team of 10 senior scientists to

define US technology strategy in pre-formulation, formulation and

analytical

. Acted as bio-analytical (LC/MS/MS) expert to help clinical group to

identify contract labs for the nicotine analysis of Plasma samples

. Provided analytical, formulation, stability and quality expert report

on a key successful due diligence (successful Xenical Rx to OTC switch

rights)

. Led GSK R&D 2005 summer Internship Program (about 25 students).

Senior Development Scientist, June 2000 to Aug 2003

. Successfully identified the unknown degradants in Nicotine Lozenge

using a combination of techniques (isolation, purification, open

column chromatography, LC/MS, NMR). FDA required the identification of

these degradants. This resulted in the One Cent NDA approval on time.

The business impact of this work was significant.

. Successfully provided CMC justification on a FDA challenge on a "ghost

peak" in nicotine degradant chromatogram.

. Successfully identified the root cause of BC Powder potency loss, and

then re-formulated to avoid the product withdraw from market

. CMC development for Nicotine Lozenge Spearmint (formulation

development, method development, validation, method transfer and

deg/impurity identification, stability). Product was successfully

approved by FDA & MAA.

. Analytical method development and validation and transfer for assay,

dissolution, content uniformity, and drug substances and impurities.

Wyeth Pharmaceutical R & D, Wyeth Consumer Healthcare (now Pfizer),

Richmond, Sept 1998 to June 2000

Manager of Herbal & Vitamin Research and Development

. Wyeth President Award of Year 1999 in recognizing the pioneer herbal

research and development work for Wyeth herbal pipeline

. Responsible for the research and development for Herbal and Vitamin

products. Managed over 20 projects with a team of 5-9 scientists

. Established a unique quality control approach using a combination of

analytical and bioassay. This was the first approach for herbal

quality control in industry. It differentiated Wyeth herbal products

from the rest of other companies.

. Implemented quality system for newly acquired company Solgar to

comply with Weyth quality system.

. Set up development capabilities of Vitamin and Herbal products, and

transferred Solgar R&D lab from new Jersey to Richmond Virgina.

. Published multiple high impact papers on the popular herbal products

including quality standards, and analytical methodologies

Pure World Botanicals, April 1997 to Aug 1998

Senior Scientist: Development of Standardized botanical extracts for

dietary supplement

EDUCATION:

Postdoctoral fellow in Natural Products Chemistry, Rutgers, The State

University of New Jersey, New Brunswick, Feb. 1995-March 1997

. Ph.D. in Natural Products Chemistry, Shanghai Institute of Materia

Medica, Chinese Academy of Sciences (CAS), July 1994

. M.S. in Organic Chemistry, Department of Chemistry, Lanzhou

University, June 1991

PUBLICATIONS:

Mira Jun, Yu Shao, Chi-Tang Ho, Uwe Koetter, Stanly Lech, Structural

Identification of Non-Volatile Degradation Products of Glucosamine by Gas

Chromatography/Mass Spectrometry, Liquid Chromatography/Mass Spectrometry

and Nuclear Magnetic Resonance Analysis, (2003) Journal of Agricultural

and Food Chemistry 51, 6240-6246.

1. Yu Shao, Chi-Tang Ho, Chee-Kok Chin, Vladirmir Badmaev, Wei Ma, and Mou-

Tuan Hwang, Inhibitory activity of boswellic acids from Boswellia

serrataainst human leukemia HL-60 cells in culture. (1998)Planta Medica

64, 328-331.

2. Yu Shao, Onoomar Poobrasert, Edward J. Kennely, Chee-Kok Chin, Chi-Tang

Ho, Mou-Tuan Huang, Stephen A. Garrison and Geoffrey A. Cordell,

Steroidal saponins from Asparagus officinalis and their antitumor

activity. (1997) Planta Medica 63, 258-262.

3. Yu Shao, Chi-Tang Ho, Chee-Kok Chin, and Geoffrey A. Cordell,

Asterlingulatosides C and D, Cytotoxic triterpenoid saponins from Aster

lingulatus. (1997)J. Nat. Prod. 60, 743-746.

4. Yu Shao, Chee-Kok Chin, Chi-Tang Ho, Wei Ma, stephen A Garrison and Mou-

Tuan Huang, Antitumor activity of the crude saponins obtained from

asparagus, (1996) Cancer Letters 104, 31-36.

5. Yu Shao, Onoomar Poobrasert, Chi-Tang Ho, Chee-Kok Chin, and Geoffery A.

Cordell, A new echinocystic acid saponin from Kalimeris shimadae, (1996)

Phytochemistry 38, 195-200.

6. Yu Shao, Chi-Tang Ho, Chee-Kok Chin, Bin Hu and Guowei Qin, Triterpenoid

saponins from Aster lingulatus. (1996)Phytochemistry 44, 337-340.

7. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell,

Asteryunnanoside F and G, two new triterpenoid saponins from Aster

yunnanensis, (1995)Planta Medica 61, 446-449.

8. Dongliang Cheng, Yu Shao, Hartman, R., and Kai Zhao, Pentapeptides from

Aster tataricus, (1996)Phytochemistry 41, 225-227.

9. Yu Shao, Nai-Shen Bai and Bing-Nan Zhou, Kaurane glycosides from Inula

britannica L. var chinensis, (1996)Phytochemistry 42, 783-786.

10. Yu Shao, Yun-Long Li and Bing-Nan Zhou, Glycosides from Aster

batangensis, (1996)Phytochemistry 41, 1593-1600.

11. Jin-Hong Chen, Yu Shao, Mou-Tuan Huang, Chee-Kok Chin and Chi-Tang Ho,

Inhibitory effect of caffeic acid phenyl ester on Hl-60 cells,

(1996)Cancer Letters108, 211-214.

12. Dong-Liang Cheng and Yu Shao, Terpene glycosides from Aster

tataricus,(1994) Phytochemistry 35, 173-176.

13. Dong-Liang Cheng and Yu Shao, Triterpenoid saponins from Acanthopanax

graldii Harms, (1993)Acta Botanica Sinica 36, 75-79.

14. Dong-Liang Cheng, Yu Shao, R. Hartman and E. Roder and K. Zhao,

Oligopeptides from Aster tataricus, (1994)Phytochemistry 36, 945-948.

15. Dong-Liang Cheng, Yu Shao, Li Yang and Pei-Xiu Zhou, The structure of a

new monoterpene glycoside from Aster tataricus, (1993)Acta Botanica

Sinica 3, 311-313.

16. Yu Shao and Bing-Nan Zhou, Asteryunnanoside C and D, Two new

triterpenoid saponins from Aster yunnanensis, (1995)Natural Product

Letters 6, 87-93.

17. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell, Triterpene

saponins from Aster yunnanensis, (1995)Phytochemistry 38, 1487-1492.

18. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and G. A. Cordell, The structure

of asterbatanoside J from Aster batangensis, (1995)Chinese Chemical

Letters 6, 221-224.

19. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell, Two new

triterpenoid saponins, asterbatanoside F and G, from Aster

batangensis,(1995) Natural Product Letters 5, 233-240.

20. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell,

Triterpenoid saponins from Aster batangensis, (1995)Phytochemistry 38,

927-933.

21. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell, Glycosides

from Aster yunnanensis, (1995)Phytochemistry 38, 675-680.

22. Yu Shao and Dong-Liang Cheng, Structure of Asterin C from Aster

tataricus, (1993) Chemical Journal of Chinese University 14, 1551-1552.

23. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu, Echinocystic acid

saponins from Aster yunnanensis, (1995)Journal of Natural Products 6,

837-842.

24. Yu Shao and Dong-Liang Cheng, Structure of Asterin C from Aster

tataricus, (1993) Chemical Journal of Chinese University 14, 1551-1552.

25. Yu Shao and Dong-Liang Cheng, Structure of Asterin C from Aster

tataricus, (1993) Chemical Journal of Chinese University 14, 1551-1552.

26. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu, Echinocystic acid

saponins from Aster yunnanensis, (1995)Journal of Natural Products 6,

837-842.

27. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu,, New triterpenoid

saponins, asterbatanoside D and E from Aster batangensis, (1995)Planta

Medica 61, 246-249.

28. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu, New medicagenic acid

saponins from Aster batangensis, (1995)Phytochemistry 39, 875-881.

29. Dong-Liang Cheng and Yu Shao, A new triterpene glycoside from Aster

tataricus, (1993) Chinese Chemical Letters 7, 605-606.

30. Yu Shao, Jin-Hai Gao and Bing-Nan Zhou, Asteryunnanoside A and B, two

new triterpenoid saponins from Aster yunnanensis, (1994)Chinese Chemical

Letters 5, 121-124.

31. Dong-Liang Cheng, Yu Shao, Yu-Xin Cui and R. Hartman, Two new

oligopeptides from Aster tataricus, (1993)Chinese Chemical Letters 11,

889-892.

32. Yu Shao, Yun-Long Li and Bing-Nan Zhou, Structural elucidation

and synthesis of asterbatanoside A from Aster batangensis, (1994)Chinese

Chemical Letters 5, 675-678.

33. Yu Shao, Nai-Shen Bai and Bing-Nan Zhou, Inuloside A and B, two new

diterpene glycosides from Inula britannica L. var chinensis,

(1994)Chinese Chemical Letters 5, 757-760.

34. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell,

Asteryunnanoside E, a new triterpenoid saponin from Aster yunnanensis,

(1994)Chinese Chemical Letters 5, 761-764.

35. Yu Shao and Bing-Nan Zhou, Two new triterpenoid saponins,

asterbatanoside B and C from Aster batangensis, (1994)Chinese Chemical

Letters 5, 835-838.

36. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu, A new triterpenoid

saponin, asteryunnanoside H, from Aster yunnanensis, (1994)Chinese

Chemical Letters 5, 839- 843.

37. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell, Two

new oleanolic acid saponins, asteryunnanoside F and G, from Aster

yunnanensis, (1994)Chinese Chemical Letters 5, 843-856.

38. Yu Shao, Bing-Nan Zhou, Kan Ma and Hou-Ming Wu, Two new triterpenoid

saponins, asterbatanoside D and E, from Aster batangensis, (1994)Chinese

Chemical letters 5, 941-944.

39. Jin-Hai Gao, Hong-Wu Wang, Guo-Qin Song, Yu Shao and Dong-Liang Cheng,

Structure and stereochemistry analysis of two compounds from Aster

tataricus by NMR, (1994)Chinese Journal of Magnetic Resonence 11, 391-

398.

40. Yu Shao, Bing-Nan Zhou, Long-Ze Lin and Geoffrey A. Cordell, Two new

triterpenoid saponins, asterbatanoside H and I, from Aster batangensis,

(1995)Chinese Chemical Letters 6, 105-108.

41. Dao-Feng Cheng, Min Zhang, Yu Shao and Hong-Liang Xu, Purification and

quantification analysis of the crude saponins from Gleditsia sinensis

Lam, (1995) Chinese Herbal Medicine 26, 401-402.

42. Binhu, Yu Shao, Guowei Qin, Chee-Kok Chin and Chi-Tang Ho, New

triterpene glycosides from Aster lingulatus, (1996) Chinese Chemical

letters, 6, 254-257.

43. Yu Shao, Chee-Kok Chin, and Chi-Tang Ho, Indole alkaloids from the

seeds of asparagus, Planta Medica, in press.

44. Yu Shao, Chi-Tang Ho, Chee-Kok Chin, Geoffrey A. Cordell, Lingulatusin,

an unusual linear diterpene from Aster lingulatus, (1998) Phytochemistry,

.

45. Mingfu Wang, Yu Shao, Tzou-Chi Huang, Guor-Jien Wei and Chi-Tang Ho,

Isolation and structural elucidation of aroma constituents bound as

glycosides from sage (Salvia officinalis), (1998) Journal of Agricltural

and Food Chemistry 46, 4869-4873.

46. Chi-Tang Ho, Jianhong Chen, Guangyuan Lu, Mou-Tuan Huang, Yu Shao and

Chee-Kok Chin, Antioxidantive and antitumorgenic properties of rosemary,

ACS symposium series book, in press.

47. Yu Shao, Kan He, Bolin Zheng and Qunyi Zheng, Quantitative and

qualitative determination of kavapyrones in Piper mycisticum by reversed-

phase high-performance liquid chromatography coupled with APCI mass

spectrometery. (1998) Journal of Chromatography A 825, 1-8.

48. Kan He, Lynn Pilkington, Yu Shao, Bolin Zheng and Qunyi Zheng,

Triterpene glycosides from Cimifuga racemosa, Phytochemistry, submitted.

49. Minfu Wang, Jiangang Li, Yu Shao, Tzou-Chi Huang, Mou-Tuan Huang, Chee-

Kok Chin, Robert T. Rosen and Chi-Tang Ho, Antioxidative and cytotoxic

components of hihbush blueberry, ACS symposium series book, in press.

50. Mingfu Wang, Yu Shao, Jiangang Li, Meera Rangarajan, Edmond J. LaVoie,

Chi-Tang Ho, Antioxidative phenolic glycosides from sage (Salvia

officnalis), (1999)J. Natural Products 62, 454-456.

51. Mingfu Wang, Jiangang Li, Yu Shao, Tzou-Chi Huang, Mou-tuan Huang, Chee-

Kok Chin, Robert T. Rosen and Chi-Tang Ho, Antioxidative and cytotoxic

components of highbush blueberry (vaccinium corymbosum. L).

(2000)Phytochemical and Phytopharmaceutical, 271-320, Edited by Fereidoon

Shahidi and Chi-Tang Ho, AOCS Press: Champaign, IL.

52. Chi-Tang Ho, Mou-Tuan Huang, You-Rong Lou, Wei Ma, Yu Shao, Guor-Jien

Wei, Mingfu Wang and Chee-Kok Chin. Antioxidant and anti-tumor activity

of rosemary leaves. (2000)Phytochemical and Phytopharmaceutical, 297-307,

Edited by Fereidoon Shahidi and Chi-Tang Ho, AOCS Press: Champaign, IL.

53. Mou-Tuan Huang, We Ma, Vladimir Balmaev, Yu Shao, Chee-Kok Chin, and

Chi-Tang Ho, Anti-tumor activity of an extract of the gum extrudate from

the tree Boswellia serrata,(2000) Phytochemical and Phytopharmaceutical,

309-313, Edited by Fereidoon Shahidi and Chi-Tang Ho, AOCS Press:

Champaign, IL.

54. Benaifer D. Dubash, Bo Lin Zheng, Calvin Hyungchan Kim, Kan He, Yu

Shao, Qun Yi Zheng, Chi-Tang Ho and Mou-Tuan Huang, Inhibitory effect of

resveratrol and related compounds on the macromolecular synthesis in Hl-

60 cells and the metabolism of 7,12-Dimethylbenz[a]anthracene by mouse

liver microsomes, (2000)Phytochemical and Phytopharmaceutical, 315-320,

Edited by Fereidoon Shahidi and Chi-Tang Ho, AOCS Press: Champaign, IL.

55. Qun Y Zheng, Kan He, Lynn Pilkington, Yu Shao, Bolin Zheng, CimiPure: a

standardized black cohosh extract with novel triterpene glycoside for

menopausal women. (2000)Phytochemical and Phytopharmaceutical, 360-370,

Edited by Fereidoon Shahidi and Chi-Tang Ho, AOCS Press: Champaign, IL.

56. Bolin Zheng, Kan He, Calvin Kim, Lingling Rogers, Yu Shao, Qunyi Zheng,

Effect of A lipid Extract from Lepidium meyenii on Sexual Behavior in

Mice and Rats, (2000) Urology 55 (4), 598-602.

57. Yu Shao, Amanda Harris, Mingfu Wang, Hongjie Zhang and Geoffrey

Cordell, Triterpene Glycosides from Cimicifuga racemosa, (2000) J. of

Nat. Prod. 63 (7), 905-910.

58. Yu Shao, Mike Mummert, Rama Alluri, Uwe Koetter, Stability-indicating

HPLC Method for Glucosamine Solid Dosage Forms, (2004) J. Biomed.

Pharm.Anal 35, 625-631.

59. Jinhai Gao, Genbin Shia, Guoqiang Song, Yu Shao, Bingnan Zhou, Further

NMR Investigation and Conformational Analysis of An Acylated Flavonol

Glucorhamnoside, (1998) Magnetic Resonance in Chemistry 34, 249-254.

Patents

1. US 6,267,995 B1, "Extract of Lipidium meyenii Roots for Pharmaceutical

Applications".

2. US 361240-201A, "Compositions and Methods for their preparation from

Lepidium".

3. China 201210417697.3, "A sustained release capsule comprising the

combination of Ibuprofen and Pseudoephedrine".

4. China ZL 201110182886.2, "A chewable tablet of Ibuprofen".

Contact this candidate